BACKGROUND: A platinum doublet has been the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) and good performance status. This treatment results in almost a doubling of 1-yr survival, along with an improvement in quality of life despite treatment-related toxicities. However, platinum-based treatment may be associated with significant toxicity. MATERIALS AND METHODS: In this trial, we prospectively evaluated a weekly regimen of docetaxel and gemcitabine for advanced NSCLC. The endpoints of this study included objective response rate, survival, and toxicity. Forty-two patients with previously untreated, advanced NSCLC with PS 0-1 were included. Patients received docetaxel (36 mg/m2) and gemcitabine (600 mg/m2) on d 1, 8, and 15 of a 28-d cycle. Responses were assessed every two cycles. The median age was 63 yr; with 22 males and 20 females; 67% were >or=60 years old; and 38 patients had stage IV disease. RESULTS: In the intent-to-treat (ITT) analysis of response, 16 patients had a partial response (38%) and 15 patients had stable disease (36%). The 1-yr survival was 48%; median survival for all patients was 11.3 mo and the median progression-free survival was 5.1 mo. Toxicities (>or= grade 3) included neutropenia (29%), asthenia (26%), diarrhea (14%), thrombocytopenia (10%), pneumonitis (7%), peripheral neuropathy (5%), peripheral edema (5%), nail changes (2%), and myositis (2%). CONCLUSIONS: This study demonstrated that this non-platinum doublet (docetaxel + gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens.
BACKGROUND: A platinum doublet has been the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) and good performance status. This treatment results in almost a doubling of 1-yr survival, along with an improvement in quality of life despite treatment-related toxicities. However, platinum-based treatment may be associated with significant toxicity. MATERIALS AND METHODS: In this trial, we prospectively evaluated a weekly regimen of docetaxel and gemcitabine for advanced NSCLC. The endpoints of this study included objective response rate, survival, and toxicity. Forty-two patients with previously untreated, advanced NSCLC with PS 0-1 were included. Patients received docetaxel (36 mg/m2) and gemcitabine (600 mg/m2) on d 1, 8, and 15 of a 28-d cycle. Responses were assessed every two cycles. The median age was 63 yr; with 22 males and 20 females; 67% were >or=60 years old; and 38 patients had stage IV disease. RESULTS: In the intent-to-treat (ITT) analysis of response, 16 patients had a partial response (38%) and 15 patients had stable disease (36%). The 1-yr survival was 48%; median survival for all patients was 11.3 mo and the median progression-free survival was 5.1 mo. Toxicities (>or= grade 3) included neutropenia (29%), asthenia (26%), diarrhea (14%), thrombocytopenia (10%), pneumonitis (7%), peripheral neuropathy (5%), peripheral edema (5%), nail changes (2%), and myositis (2%). CONCLUSIONS: This study demonstrated that this non-platinum doublet (docetaxel + gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens.
Authors: M Hejna; G V Kornek; M Raderer; H Ulrich-Pur; W C Fiebiger; L Marosi; B Schneeweiss; R Greul; W Scheithauer Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: V Georgoulias; E Papadakis; A Alexopoulos; X Tsiafaki; A Rapti; M Veslemes; P Palamidas; I Vlachonikolis Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: J F Vansteenkiste; J E Vandebroek; K L Nackaerts; P Weynants; Y J Valcke; D A Verresen; R C Devogelaere; S A Marien; Y P Humblet; N L Dams Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: K Roszkowski; A Pluzanska; M Krzakowski; A P Smith; E Saigi; U Aasebo; A Parisi; N Pham Tran; R Olivares; J Berille Journal: Lung Cancer Date: 2000-03 Impact factor: 5.705
Authors: Tarek Mekhail; Thomas E Hutson; Paul Elson; G Thomas Budd; Gordon Srkalovic; Thomas Olencki; David Peereboom; Robert Pelley; Ronald M Bukowski Journal: Cancer Date: 2003-01-01 Impact factor: 6.860